Study reports potential target and compounds to slow the development of Alzheimer's disease

Researchers have discovered a potential biomarker for Alzheimer's disease diagnosis that may also serve as a therapeutic target. Examining cerebrospinal fluid samples from patients with cognitive impairment ranging from subjective impairment to a diagnosis of Alzheimer's disease, they found a shift in the profile of specialized liquid mediators from pro-resolving to pro-inflammatory.